Safety and Tolerability of NN9068 in Healthy Male Volunteers

NCT00983021 · Completed

Last updated 2026-05-28

This clinical trial tests the safety and tolerability of the investigational drug NN9068 in healthy adult men.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 24 people

Who can join Ages 18–55 · male only

Timeline Started 2009-09 · est. completion 2009-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT00983021 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068. The trial participants will be randomised to 4 different treatments in trial, receiving trial products in a pre-defined order.

Treatments tested

insulin degludec/liraglutide also known as NN9068 Drug

Single, simultaneous dose of NN9068, injected s.c. (under the skin)
insulin degludec also known as NN1250 Drug

Single, simultaneous dose of NN1250, injected s.c. (under the skin)
liraglutide also known as NN2211 Drug

Single, simultaneous dose of NN2211, injected s.c. (under the skin)
placebo Drug

Single, simultaneous dose of placebo, injected s.c. (under the skin)

Main thing measured	Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00983021 ↗